CFOR

SEC source: 0001140361-17-028091 · doc1.xml · nonDerivative · entry 1

DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,966

SEC source: 0001140361-17-027562 · doc1.xml · derivative · entry 1

jVen Capital, LLC · CIK 0001641611 · Director · Chairman and CEO · 10% owner

JONES EVAN/ FA · CIK 0001020741 · Chief Executive Officer

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,730

Underlying: Common Stock · 158,730 shares

Expires 2023-07-05

F1 · security: Issuance of warrants pursuant to that certain Amended & Restated Note Purchase Agreement dated July 10, 2017.

F2 · ownership.direct: Evan Jones, the Chairman of the Board and the Chief Executive Officer of OpGen, Inc. (the "Company"), is the managing member of jVen Capital, LLC and is the indirect beneficial owner of all shares of the Company's Common Stock owned by jVen Capital, LLC.

SEC source: 0001140361-17-028657 · doc1.xml · derivative · entry 1

jVen Capital, LLC · CIK 0001641611 · Director · Chairman and CEO · 10% owner

JONES EVAN/ FA · CIK 0001020741 · Chief Executive Officer

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,730

Underlying: Common Stock · 158,730 shares

Expires 2022-07-05

F1 · security: Issuance of warrants pursuant to that certain Amended & Restated Note Purchase Agreement dated July 10, 2017.

F2 · derivative.exercise_price: The purpose of this Form 4/A is to correct the exercise price and expiration date for this warrant issuance.

F2 · derivative.expiration_date: The purpose of this Form 4/A is to correct the exercise price and expiration date for this warrant issuance.

F3 · ownership.direct: Evan Jones, the Chairman of the Board and the Chief Executive Officer of OpGen, Inc. (the "Company"), is the managing member of jVen Capital, LLC and is the indirect beneficial owner of all shares of the Company's Common Stock owned by jVen Capital, LLC.

SEC source: 0001140361-17-027360 · doc1.xml · derivative · entry 1

jVen Capital, LLC · CIK 0001641611 · Director · Chairman and CEO · 10% owner

JONES EVAN/ FA · CIK 0001020741 · Chief Executive Officer

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,423

Underlying: Common Stock · 70,423 shares

Expires 2022-06-28

F1 · security: Issuance of warrants pursuant to that certain Note Purchase Agreement dated May 31, 2017.

F2 · ownership.direct: Evan Jones, the Chairman of the Board and the Chief Executive Officer of OpGen, Inc. (the "Company"), is the managing member of jVen Capital, LLC and is the indirect beneficial owner of all shares of the Company's Common Stock and derivative securities owned by jVen Capital, LLC.

SEC source: 0001140361-17-027561 · doc1.xml · derivative · entry 1

jVen Capital, LLC · CIK 0001641611 · Director · Chairman and CEO · 10% owner

JONES EVAN/ FA · CIK 0001020741 · Chief Executive Officer

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,788

Underlying: Common Stock · 149,788 shares

Expires 2022-06-28

F1 · security: The purpose of this Form 4/A is to report an increase in the number of Warrants to purchase Common Stock issued to jVen Capital, LLC pursuant to an amendment and restatement of that certain Note Purchase Agreement dated May 31, 2017.

F2 · security: Issuance of warrants pursuant to that certain amended and restated Note Purchase Agreement dated July 10, 2017.

F3 · ownership.direct: Evan Jones, the Chairman of the Board and the Chief Executive Officer of OpGen, Inc. (the "Company"), is the managing member of jVen Capital, LLC and is the indirect beneficial owner of all shares of the Company's Common Stock owned by jVen Capital, LLC.

SEC source: 0001140361-17-028656 · doc1.xml · derivative · entry 1

jVen Capital, LLC · CIK 0001641611 · Director · Chairman and CEO · 10% owner

JONES EVAN/ FA · CIK 0001020741 · Chief Executive Officer

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,845

Underlying: Common Stock · 140,845 shares

Expires 2022-06-28

F1 · security: The purpose of this Form 4/A is to report the correct increase in the number of Warrants to purchase Common Stock issued to jVen Capital, LLC pursuant to an amendment and restatement of that certain Note Purchase Agreement dated May 31, 2017.

F2 · security: Issuance of warrants pursuant to that certain amended and restated Note Purchase Agreement dated July 10, 2017.

F3 · ownership.direct: Evan Jones, the Chairman of the Board and the Chief Executive Officer of OpGen, Inc. (the "Company"), is the managing member of jVen Capital, LLC and is the indirect beneficial owner of all shares of the Company's Common Stock owned by jVen Capital, LLC.

SEC source: 0000899243-18-003274 · doc5.xml · derivative · entry 1

Merck & Co., Inc. · CIK 0000310158 · 10% owner

Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner

Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,120

Underlying: Common Stock · 13,120 shares

Expires 2022-06-28

F1 · derivative.exercise_price: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018.

F1 · shares: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018.

F1 · derivative.underlying_shares: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018.

F1 · balance_after: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018.

F2 · ownership.nature: These securities are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.

SEC source: 0001140361-17-024690 · doc1.xml · derivative · entry 1

Nova Tina Susan · CIK 0001302605 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2027-06-08

F1 · derivative.exercise_date: The option vests 25% on each of July 1, 2017, October 1, 2017, January 1, 2018 and April 1, 2018.

SEC source: 0001140361-17-024688 · doc1.xml · derivative · entry 1

Harris Timothy J.R. · CIK 0001419958 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2027-06-08

F1 · derivative.exercise_date: The option vests 25% on each of July 1, 2017, October 1, 2017, January 1, 2018 and April 1, 2018.

SEC source: 0001140361-17-024687 · doc1.xml · derivative · entry 1

D'Andrea Harry J · CIK 0001381642 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2027-06-08

F1 · derivative.exercise_date: The option vests 25% on each of July 1, 2017, October 1, 2017, January 1, 2018 and April 1, 2018.

SEC source: 0001140361-17-024692 · doc1.xml · derivative · entry 1

Ushio Misti · CIK 0001397963 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2027-06-08

F1 · derivative.exercise_date: The option vests 25% on each of July 1, 2017, October 1, 2017, January 1, 2018 and April 1, 2018.

SEC source: 0001140361-17-018612 · doc1.xml · derivative · entry 1

Nova Tina Susan · CIK 0001302605 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2027-05-04

F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on May 4, 2018.

SEC source: 0001140361-17-009454 · doc1.xml · derivative · entry 1

JONES EVAN/ FA · CIK 0001020741 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2027-02-23

F1 · derivative.exercise_date: The option vests 25% on February 23, 2018 and 6.25% quarterly thereafter on the first business day of each quarter for a period of three years.

SEC source: 0001140361-17-009452 · doc1.xml · derivative · entry 1

DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,000

Underlying: Common Stock · 68,000 shares

Expires 2027-02-23

F1 · derivative.exercise_date: The option vests 25% on February 23, 2018 and 6.25% quarterly thereafter on the first business day of each quarter for a period of three years.

SEC source: 0001140361-17-005767 · doc1.xml · derivative · entry 2

DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,750

Underlying: Common Stock · 6,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: On November 10, 2016, one-fourth of a restricted stock unit award granted on November 10, 2015 vested and was earned, but the transaction was not reported on a timely basis.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments from the date of grant with the first installment having vested on November 10, 2016, with acceleration of vesting in certain circumstances associated with a change of control.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments from the date of grant with the first installment having vested on November 10, 2016, with acceleration of vesting in certain circumstances associated with a change of control.

SEC source: 0001140361-17-005767 · doc1.xml · nonDerivative · entry 1

DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,966

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: On November 10, 2016, one-fourth of a restricted stock unit award granted on November 10, 2015 vested and was earned, but the transaction was not reported on a timely basis.

SEC source: 0000899243-16-023850 · doc4.xml · derivative · entry 2

Merck & Co., Inc. · CIK 0000310158 · 10% owner

Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner

Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,950,821

Underlying: Common Stock · 2,050,821 shares

Expires 2021-06-27

F1 · price: The reported securities were included within units ("Units") with each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the "Common Stock") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit.

F2 · ownership.nature: These securities are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.

SEC source: 0000899243-16-023850 · doc4.xml · nonDerivative · entry 1

Merck & Co., Inc. · CIK 0000310158 · 10% owner

Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner

Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,413,449

F1 · price: The reported securities were included within units ("Units") with each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the "Common Stock") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit.

F2 · ownership.nature: These securities are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.

SEC source: 0000899243-16-020819 · doc4.xml · derivative · entry 3

Merck & Co., Inc. · CIK 0000310158 · 10% owner

Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner

Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,685,248

Underlying: Common Stock · 4,785,248 shares

Expires not disclosed

F3 · price: Represents future obligation of MGHIF to purchase additional Units for a purchase price of $1.14375 per Unit within 60 days and subject to stockholder consent and notice to stockholders of same (including the filing of Schedule 14C and the twenty day waiting period), pursuant to the Amended and Restated Securities Purchase Agreement entered into on May 18, 2016.

F3 · derivative.exercise_date: Represents future obligation of MGHIF to purchase additional Units for a purchase price of $1.14375 per Unit within 60 days and subject to stockholder consent and notice to stockholders of same (including the filing of Schedule 14C and the twenty day waiting period), pursuant to the Amended and Restated Securities Purchase Agreement entered into on May 18, 2016.

F3 · derivative.expiration_date: Represents future obligation of MGHIF to purchase additional Units for a purchase price of $1.14375 per Unit within 60 days and subject to stockholder consent and notice to stockholders of same (including the filing of Schedule 14C and the twenty day waiting period), pursuant to the Amended and Restated Securities Purchase Agreement entered into on May 18, 2016.

F2 · ownership.nature: These shares are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.

SEC source: 0000899243-16-020819 · doc4.xml · derivative · entry 2

Merck & Co., Inc. · CIK 0000310158 · 10% owner

Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner

Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 900,000

Underlying: Common Stock · 900,000 shares

Expires 2021-05-19

F1 · price: The reported securities are included within units ("Units") each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the "Common Stock") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit.

F2 · ownership.nature: These shares are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.

SEC source: 0000899243-16-020819 · doc4.xml · nonDerivative · entry 1

Merck & Co., Inc. · CIK 0000310158 · 10% owner

Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner

Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,679,022

F1 · price: The reported securities are included within units ("Units") each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the "Common Stock") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit.

F2 · ownership.nature: These shares are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.